Navigation Links
Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
Date:1/23/2012

human clinical trials, and educating the medical community regarding appropriate use of these new procedures and technologies. By providing research, evaluation, and education under one roof, CRF has a unique ability to generate important research questions, test and refine groundbreaking new therapies, and ensure that these treatments are available to patients at the earliest opportunity. For more information, please visit www.celltherapy.crf.org.

About NeoStem, Inc. and Amorcyte, LLC, a NeoStem companyNeoStem, Inc. ("NeoStem") is a leader in the development and manufacture of cell therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. That manufacturing base is one of the few cGMP facilities available for contracting in the burgeoning cell therapy industry, and it is the combination of PCT's core expertise in manufacturing and NeoStem's extensive research capabilities that positions the company as a leader in cell therapy development. Amorcyte, LLC, also a NeoStem company, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and is open for enrollment in a Phase 2 trial for the preservation of heart function after a heart attack.  Amorcyte expects to begin a Phase 1 clinical trial in 2012 for AMR-001 for the treatment of patients with congestive heart failure. Athelos Corporation, also a NeoStem company, is developing a T-cell therapy for a range of autoimmune conditions with our partner Becton-Dickinson.  NeoStem's pre-clinical assets include its VSEL™ Technology platform for regenerative medicine, which NeoStem believes to be an endogenous, pluripotent, non-embryonic stem cell that has the potential to change the paradigm of cell therapy as
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Darius Naigamwalla Appointed Senior Vice President and Head of the Brand Management Practice at Campbell Alliance
2. SCAN Health Plan Offers Seniors Five Tips to Prepare for Surgery
3. Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US
4. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
5. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
6. Anesiva Announces Appointment of William Houghton, M.D. as Senior Vice President and Chief Medical Officer
7. On-Line Medicare Advisor Saves Seniors Time, Hassle and Money
8. Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources
9. ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development
10. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
11. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Mexico Biomedical Sensors Market - Growth, ... The Mexico Biomedical Sensors market ... CAGR of 2.68% over the period 2014-2020 ... adaptable to the genetic formulation of each individual. These ...
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Middle East & Africa Biomedical Sensors Market - Growth, ... The Middle East ... $0.84 billion by 2018 at a CAGR of 3.26% ... will bring Biomedical sensors that are adaptable to the ...
(Date:8/31/2015)... Aug. 31, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is pleased to announce that its wholly owned ... lead candidate, PPL-003, to an Investigational New Drug (IND) ... and uveitis.  PPL recently completed a study in a ... solution achieved highly significant efficacy and a more rapid ...
(Date:8/31/2015)... 31, 2015  US-Australian drug discovery company, Novogen ... confirmed its comprehensive scientific review has identified high ... areas of unmet patient need. Novogen is moving ... projects prior to entering into Phase 1 clinical ... Acting Chief Executive Officer, Iain Ross , ...
Breaking Biology Technology:Mexico Biomedical Sensors Market Report 2015-2020 2Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6
... (Nasdaq: OREX ), a biopharmaceutical company focused on ... third quarter ended September 30,2010 on Wednesday, November 3, 2010 ... a live webcast and conference call at 5:00 p.m. Eastern ... and webcast to discuss financial results and recent business highlights. ...
... (Nasdaq: UTHR ) today announced its results of operations ... for the third quarter of 2010 were $171.0 million, up from ... the third quarter of 2010 was $39.7 million, or $0.70 per ... per basic share, for the same quarter in 2009. Gross margin ...
... the Human Genome -- REYKJAVIK, Iceland, October 27, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Biology Technology:United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 2United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 3United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 4United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 5United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 6United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 7The New deCODE Map of the Human Genome 2The New deCODE Map of the Human Genome 3The New deCODE Map of the Human Genome 4The New deCODE Map of the Human Genome 5The New deCODE Map of the Human Genome 6The New deCODE Map of the Human Genome 7The New deCODE Map of the Human Genome 8The New deCODE Map of the Human Genome 9
(Date:8/12/2015)... August 12, 2015 As the ... payment innovation and advanced biometrics technology is accelerating beyond ... consumers rely on using their credit cards, the digital ... future for payment services led by companies in the ... :  Google, Inc. (NASDAQ: GOOG ), Apple Inc. ...
(Date:8/11/2015)... 2015 Today, ZUK announced its Android smartphone ... as expected revenues in 2015 that relate to sales of FPC1155 ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO ... prominent smartphone manufacturer in China ... FPC1 155 for Z1 , ...
(Date:8/6/2015)... 6, 2015  Today, U.S. Congressman Mike ... ™ to learn firsthand how Silicon Valley technologies ... is a world leader in multi-factor identity management ... helping federal agencies and commercial organizations achieve new ... "The vast majority of network breaches can ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2
... Active management of the third stage of labour means ... approach, reveals a thesis from the University of Gothenburg, Sweden, ... studies in the West have shown that heavy bleeding following ... thesis, midwife and researcher Elisabeth Jangsten decided to look at ...
... ANN ARBOR, Mich---University of Michigan researchers have determined ... tumors, providing new evidence that the deadliest form of ... cancer stem cell model. In addition, the researchers ... by switching various genes on and off, making the ...
... the massive glaciers of the greater Himalayan region are ... help the region,s communities prepare for the many ways ... to a new report. Programs that integrate health, education, ... address these impacts, the report states. "The extremely high ...
Cached Biology News:Active management of the third stage of labor reduces risk of bleeding 2More evidence that melanoma does not conform to the cancer stem cell model 2More evidence that melanoma does not conform to the cancer stem cell model 3Time to prepare for climate change 2Time to prepare for climate change 3Time to prepare for climate change 4Time to prepare for climate change 5
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... was developed for culturing hybrid cells that ... consists of doubling the amino acids and ... concentrations have been altered as well. This ... liter, which may render it unsuitable for ...
... is an 18 amino acid synthetic peptide whose sequence corresponds to ... peptide is (amino to carboxy terminus): M(1) - A - S ... A - S - P - R - D - A ... peptide may be used for neutralization and control experiments with the ...
... EpiTect Bisulfite Kit enables complete conversion ... less than 6 hours. The highly ... against DNA degradation and a spin-column-based ... fast and reliable results for all ...
Biology Products: